Notizia - Recent Pharma, Healthcare and Biotech Happenings

Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenotype Interstitial Lung Disease - ILD – a group of a large number of lung disorders resulting in scarring or fibrosis of lungs, caused by conditions such as autoimmune ILD, hypersensitivity pneumonitis and idiopathic nonspecific interstitial pneumonia. Referred to a group of more than 100 lung disorders, chronic fibrosing Interstitial lung disease is characterized by inflammation and lung scarring, making it hard for lungs to receive enough oxygen.   The first-ever drug Ofev is an oral t...